These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29028802)

  • 1. Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination.
    van den Biggelaar AHJ; Richmond PC; Fuery A; Anderson D; Opa C; Saleu G; Lai M; Francis JP; Alpers MP; Pomat WS; Lehmann D
    PLoS One; 2017; 12(10):e0185877. PubMed ID: 29028802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
    Licciardi PV; Toh ZQ; Clutterbuck EA; Balloch A; Marimla RA; Tikkanen L; Lamb KE; Bright KJ; Rabuatoka U; Tikoduadua L; Boelsen LK; Dunne EM; Satzke C; Cheung YB; Pollard AJ; Russell FM; Mulholland EK
    J Allergy Clin Immunol; 2016 Jun; 137(6):1772-1779.e11. PubMed ID: 26825000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
    Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
    Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.
    Gaultier GN; McCready W; Ulanova M
    BMC Immunol; 2019 Nov; 20(1):41. PubMed ID: 31718534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial.
    Pomat WS; van den Biggelaar AH; Phuanukoonnon S; Francis J; Jacoby P; Siba PM; Alpers MP; Reeder JC; Holt PG; Richmond PC; Lehmann D;
    PLoS One; 2013; 8(2):e56698. PubMed ID: 23451070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
    Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
    Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration and high avidity of pneumococcal antibodies persist at least 4 years after immunization with pneumococcal conjugate vaccine in infancy.
    Ekström N; Ahman H; Palmu A; Grönholm S; Kilpi T; Käyhty H;
    Clin Vaccine Immunol; 2013 Jul; 20(7):1034-40. PubMed ID: 23658394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
    Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
    Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
    Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
    Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia.
    Lindström V; Aittoniemi J; Salmenniemi U; Käyhty H; Huhtala H; Sinisalo M
    Hum Vaccin Immunother; 2019; 15(12):2910-2913. PubMed ID: 31216225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil.
    Ho YL; Brandão AP; de Cunto Brandileone MC; Lopes MH
    Vaccine; 2013 Aug; 31(37):4047-53. PubMed ID: 23684823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
    Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serologic response to pneumococcal vaccination in children experiencing recurrent invasive pneumococcal disease.
    Ingels HAS; Kantsø B; Slotved HC
    BMC Infect Dis; 2018 Aug; 18(1):366. PubMed ID: 30081840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
    Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
    PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea.
    Pomat WS; Lehmann D; Sanders RC; Lewis DJ; Wilson J; Rogers S; Dyke T; Alpers MP
    Infect Immun; 1994 May; 62(5):1848-53. PubMed ID: 8168948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean children.
    Orami T; Ford R; Kirkham LA; Thornton R; Corscadden K; Richmond PC; Pomat WS; van den Biggelaar AHJ; Lehmann D;
    Vaccine; 2020 Nov; 38(50):7977-7988. PubMed ID: 33121845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memory B cell response to a PCV-13 booster in 3.5year old children primed with either PCV-7 or PCV-13.
    Trück J; Thompson A; Morales-Aza B; Clutterbuck EA; Voysey M; Clarke E; Snape MD; Kelly DF; Finn A; Pollard AJ
    Vaccine; 2017 May; 35(20):2701-2708. PubMed ID: 28392142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.